Imidazo[1,5-c]pyrimidin-5-amine | 2306271-00-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Imidazo[1,5-c]pyrimidin-5-amine
• CAS: 2306271-00-9
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: AYAANPYSSZGMDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
  申请人：Arnold D. Lee

  公开号：US20060235031A1

  公开（公告）日：2006-10-19

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  公式如下的化合物及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，能够抑制IGF-1R酶，适用于治疗和/或预防增生性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和疾病。
• 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
  申请人：Arnold Lee D.

  公开号：US20090118499A1

  公开（公告）日：2009-05-07

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该公式化合物及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，可抑制IGF-1R酶，用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病和中枢神经系统疾病和病症。
• Bicyclic protein kinase inhibitors
  申请人：Crew Philip Andrew

  公开号：US20070149521A1

  公开（公告）日：2007-06-28

  Compounds of the Formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该公式的化合物及其药用可接受盐，其中X1，X2，X3，X4，X5，X6，X7，R1和Q1在此定义，抑制蛋白激酶酶，并且对于治疗和/或预防过度增殖性疾病，例如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统疾病和情况，中枢神经系统疾病和情况是有用的。
• 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2168968A1

  公开（公告）日：2010-03-31

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  式 (I) 的化合物 及其药学上可接受的盐，其中 X1、X2、X3、X4、X5、X6、X7、R1 和 Q1 在此定义，抑制 IGF-1R 酶，可用于治疗和/或预防过度增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和病症、中枢神经系统疾病和病症。
• BICYCLIC PROTEIN KINASE INHIBITORS
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP1957496B1

  公开（公告）日：2012-10-24